Tulavi Therapeutics Gains Premier Breakthrough Designation for Nerve Care

The allay Hydrogel Cap represents a significant shift in peripheral nerve surgery, offering a sutureless, in situ forming barrier that supports recovery. By shielding injured nerves during the critical healing window, the device prevents axons from growing erratically—a common complication that leads to chronic residual limb pain and phantom limb sensations. With approximately 600,000 amputations and nearly 2 million peripheral nerve surgeries occurring annually in the U.S., the clinical need for such preventative technology remains substantial.

Josh Vose, CEO of Tulavi, stated that the partnership creates a vital pathway for clinicians and organizations to adopt this novel approach. Premier grants its Breakthrough Technology status only to innovations demonstrating clear advantages in patient safety and clinical outcomes. The device leverages a proprietary hydrogel platform already utilized in over 10 million procedures worldwide, now specifically engineered to address the persistent, burning pain associated with post-surgical neuromas.